TY - JOUR
T1 - Recommendations for the management of herpes zoster
AU - Dworkin, Robert H.
AU - Johnson, Robert W.
AU - Breuer, Judith
AU - Gnann, John W.
AU - Levin, Myron J.
AU - Backonja, Miroslav
AU - Betts, Robert F.
AU - Gershon, Anne A.
AU - Haanpää, Maija L.
AU - McKendrick, Michael W.
AU - Nurmikko, Turo J.
AU - Oaklander, Anne Louise
AU - Oxman, Michael N.
AU - Pavan-Langston, Deborah
AU - Petersen, Karin L.
AU - Rowbotham, Michael C.
AU - Schmader, Kenneth E.
AU - Stacey, Brett R.
AU - Tyring, Stephen K.
AU - Van Wijck, Albert J.M.
AU - Wallace, Mark S.
AU - Wassilew, Sawko W.
AU - Whitley, Richard J.
N1 - Funding Information:
which the treatment recommendations were based was sponsored by the International Association for the Study of Pain Neuropathic Pain Special Interest Group, the Neuropathic Pain Institute, and the VZV Research Foundation. Participants were selected on the basis of research and clinical expertise relevant to HZ and its management and represent the fields of anesthesiology, geriatrics, infectious diseases, internal medicine, neurology, ophthalmology, outcomes research, pain management, and virology. Relevant publications were identified by Medline searches, examination of reference lists of published articles and book chapters, and the personal knowledge of the authors. Before the meeting, all participants were provided copies of systematic literature reviews and meta-analyses [118– 121], existing guidelines relevant to the management of HZ [122–125], and published randomized clinical trials, discussed below. This literature and the authors’ clinical and research experience were reviewed during the consensus meeting, which was chaired by the first 2 authors. Information on additional randomized trials that were not identified before the meeting was provided on request after the meeting. Recommendations for practice guidelines [126], best-evidence synthesis [127], and narrative systematic reviews [128] were followed in developing recommendations for the management of HZ and summarizing the literature on which they are based. The initial version of the present article was prepared by the first 5 authors, revised by the other authors, and recirculated until all authors agreed with the text.
Funding Information:
Financial support. The consensus meeting on which these recommendations are based was supported by unrestricted grants to the University of Rochester Office of Professional Education from the International Association for the Study of Pain Neuropathic Pain Special Interest Group, the Neuropathic Pain Institute, and the VZV Research Foundation.
Funding Information:
Supplement sponsorship. This article was published as part of a supplement entitled “Recommendations for the Management of Herpes Zoster,” sponsored by the International Association for the Study of Pain Neuropathic Pain Special Interest Group, the Neuropathic Pain Institute, and the VZV Research Foundation.
PY - 2007/1/1
Y1 - 2007/1/1
N2 - The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact on quality of life, and costs of treatment. Systematic literature reviews, published randomized clinical trials, existing guidelines, and the authors' clinical and research experience relevant to the management of patients with HZ were reviewed at a consensus meeting. The results of controlled trials and the clinical experience of the authors support the use of acyclovir, brivudin (where available), famciclovir, and valacyclovir as first-line antiviral therapy for the treatment of patients with HZ. Specific recommendations for the use of these medications are provided. In addition, suggestions are made for treatments that, when used in combination with antiviral therapy, may further reduce pain and other complications of HZ.
AB - The objective of this article is to provide evidence-based recommendations for the management of patients with herpes zoster (HZ) that take into account clinical efficacy, adverse effects, impact on quality of life, and costs of treatment. Systematic literature reviews, published randomized clinical trials, existing guidelines, and the authors' clinical and research experience relevant to the management of patients with HZ were reviewed at a consensus meeting. The results of controlled trials and the clinical experience of the authors support the use of acyclovir, brivudin (where available), famciclovir, and valacyclovir as first-line antiviral therapy for the treatment of patients with HZ. Specific recommendations for the use of these medications are provided. In addition, suggestions are made for treatments that, when used in combination with antiviral therapy, may further reduce pain and other complications of HZ.
UR - http://www.scopus.com/inward/record.url?scp=33845634835&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33845634835&partnerID=8YFLogxK
U2 - 10.1086/510206
DO - 10.1086/510206
M3 - Review article
C2 - 17143845
AN - SCOPUS:33845634835
VL - 44
SP - S1-S26
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
SN - 1058-4838
IS - SUPPL. 1
ER -